|
1.
|
Montanez JE, Peters JM, Correll JB, Gonzalez FJ, Patterson AD. Metabolomics: an essential tool to understand the function of peroxisome proliferator-activated receptor alpha. Toxicol Pathol. 2013; 41(2):410-8.
|
|
|
|
|
2.
|
Khozoie C, Borland MG, Zhu B, Baek S, John S, Hager GL, Shah YM, Gonzalez FJ, Peters JM. Analysis of the peroxisome proliferator-activated receptor-ß/d (PPARß/d) cistrome reveals novel co-regulatory role of ATF4. BMC Genomics. 2012; 13:665.
|
|
|
|
|
3.
|
Albrecht PP, Torsell NE, Krishnan P, Ehresman DJ, Frame SR, Chang SC, Butenhoff JL, Kennedy GL, Gonzalez FJ, Peters JM. A Species Difference in the Peroxisome Proliferator-Activated Receptor a-Dependent Response to the Developmental Effects of Perfluorooctanoic Acid. Toxicol Sci. 2013 Feb; 131(2):568-82.
|
|
|
|
|
4.
|
Zhu B, Khozoie C, Bility MT, Ferry CH, Blazanin N, Glick AB, Gonzalez FJ, Peters JM. Peroxisome proliferator-activated receptor ß/d cross talks with E2F and attenuates mitosis in HRAS-expressing cells. Mol Cell Biol. 2012 Jun; 32(11):2065-82.
|
|
|
|
|
5.
|
Peters JM, Shah YM, Gonzalez FJ. The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer. 2012 Mar; 12(3):181-95.
|
|
|
|
|
6.
|
Peters JM, Foreman JE, Gonzalez FJ. Dissecting the role of peroxisome proliferator-activated receptor-ß/d (PPARß/d) in colon, breast, and lung carcinogenesis. Cancer Metastasis Rev. 2011 Dec; 30(3-4):619-40.
|
|
|
|
|
7.
|
Peters JM, Gonzalez FJ. Why toxic equivalency factors are not suitable for perfluoroalkyl chemicals. Chem Res Toxicol. 2011 Oct 17; 24(10):1601-9.
|
|
|
|
|
8.
|
Monk JM, Kim W, Callaway E, Turk HF, Foreman JE, Peters JM, He W, Weeks B, Alaniz RC, McMurray DN, Chapkin RS. Immunomodulatory action of dietary fish oil and targeted deletion of intestinal epithelial cell PPARd in inflammation-induced colon carcinogenesis. Am J Physiol Gastrointest Liver Physiol. 2012 Jan 1; 302(1):G153-67.
|
|
|
|
|
9.
|
Patterson AD, Peters JM. PPAR action in insulin resistance unraveled by metabolomics: potential clinical implications. Genome Med. 2011; 3(8):54.
|
|
|
|
|
10.
|
Borland MG, Khozoie C, Albrecht PP, Zhu B, Lee C, Lahoti TS, Gonzalez FJ, Peters JM. Stable over-expression of PPARß/d and PPAR? to examine receptor signaling in human HaCaT keratinocytes. Cell Signal. 2011 Dec; 23(12):2039-50.
|
|
|
|
|
11.
|
Foreman JE, Chang WC, Palkar PS, Zhu B, Borland MG, Williams JL, Kramer LR, Clapper ML, Gonzalez FJ, Peters JM. Functional characterization of peroxisome proliferator-activated receptor-ß/d expression in colon cancer. Mol Carcinog. 2011 Nov; 50(11):884-900.
|
|
|
|
|
12.
|
Daoudi M, Hennuyer N, Borland MG, Touche V, Duhem C, Gross B, Caiazzo R, Kerr-Conte J, Pattou F, Peters JM, Staels B, Lestavel S. PPARß/d activation induces enteroendocrine L cell GLP-1 production. Gastroenterology. 2011 May; 140(5):1564-74.
|
|
|
|
|
13.
|
Zhu B, Bai R, Kennett MJ, Kang BH, Gonzalez FJ, Peters JM. Chemoprevention of chemically induced skin tumorigenesis by ligand activation of peroxisome proliferator-activated receptor-beta/delta and inhibition of cyclooxygenase 2. Mol Cancer Ther. 2010 Dec; 9(12):3267-77.
|
|
|
|
|
14.
|
Omiecinski CJ, Vanden Heuvel JP, Perdew GH, Peters JM. Xenobiotic metabolism, disposition, and regulation by receptors: from biochemical phenomenon to predictors of major toxicities. Toxicol Sci. 2011 Mar; 120 Suppl 1:S49-75.
|
|
|
|
|
15.
|
Palkar PS, Anderson CR, Ferry CH, Gonzalez FJ, Peters JM. Effect of prenatal peroxisome proliferator-activated receptor alpha (PPARalpha) agonism on postnatal development. Toxicology. 2010 Sep 30; 276(1):79-84.
|
|
|
|
|
16.
|
Palkar PS, Borland MG, Naruhn S, Ferry CH, Lee C, Sk UH, Sharma AK, Amin S, Murray IA, Anderson CR, Perdew GH, Gonzalez FJ, Müller R, Peters JM. Cellular and pharmacological selectivity of the peroxisome proliferator-activated receptor-beta/delta antagonist GSK3787. Mol Pharmacol. 2010 Sep; 78(3):419-30.
|
|
|
|
|
17.
|
Sharma AK, Sk UH, He P, Peters JM, Amin S. Synthesis of isosteric selenium analog of the PPARbeta/delta agonist GW501516 and comparison of biological activity. Bioorg Med Chem Lett. 2010 Jul 15; 20(14):4050-2.
|
|
|
|
|
18.
|
Genovese S, Foreman JE, Borland MG, Epifano F, Gonzalez FJ, Curini M, Peters JM. A natural propenoic acid derivative activates peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta). Life Sci. 2010 Mar 27; 86(13-14):493-8.
|
|
|
|
|
19.
|
Vittoria Simonini M, Polak PE, Boullerne AI, Peters JM, Richardson JC, Feinstein DL. Regulation of oligodendrocyte progenitor cell maturation by PPARd: effects on bone morphogenetic proteins. ASN Neuro. 2010; 2(1):e00025.
|
|
|
|
|
20.
|
Foreman JE, Sorg JM, McGinnis KS, Rigas B, Williams JL, Clapper ML, Gonzalez FJ, Peters JM. Regulation of peroxisome proliferator-activated receptor-beta/delta by the APC/beta-CATENIN pathway and nonsteroidal antiinflammatory drugs. Mol Carcinog. 2009 Oct; 48(10):942-52.
|
|
|
|
|
21.
|
Bility MT, Zhu B, Kang BH, Gonzalez FJ, Peters JM. Ligand activation of peroxisome proliferator-activated receptor-beta/delta and inhibition of cyclooxygenase-2 enhances inhibition of skin tumorigenesis. Toxicol Sci. 2010 Jan; 113(1):27-36.
|
|
|
|
|
22.
|
Foreman JE, Sharma AK, Amin S, Gonzalez FJ, Peters JM. Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) inhibits cell growth in a mouse mammary gland cancer cell line. Cancer Lett. 2010 Feb 28; 288(2):219-25.
|
|
|
|
|
23.
|
Peters JM, Gonzalez FJ. Sorting out the functional role(s) of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) in cell proliferation and cancer. Biochim Biophys Acta. 2009 Dec; 1796(2):230-41.
|
|
|
|
|
24.
|
Foreman JE, Chang SC, Ehresman DJ, Butenhoff JL, Anderson CR, Palkar PS, Kang BH, Gonzalez FJ, Peters JM. Differential hepatic effects of perfluorobutyrate mediated by mouse and human PPAR-alpha. Toxicol Sci. 2009 Jul; 110(1):204-11.
|
|
|
|
|
25.
|
Ghosh M, Ai Y, Narko K, Wang Z, Peters JM, Hla T. PPARdelta is pro-tumorigenic in a mouse model of COX-2-induced mammary cancer. Prostaglandins Other Lipid Mediat. 2009 Apr; 88(3-4):97-100.
|
|
|
|
|
26.
|
Gopinathan L, Hannon DB, Peters JM, Vanden Heuvel JP. Regulation of peroxisome proliferator-activated receptor-alpha by MDM2. Toxicol Sci. 2009 Mar; 108(1):48-58.
|
|
|
|
|
27.
|
Gopinathan L, Hannon DB, Smith Iii RW, Peters JM, Vanden Heuvel JP. Regulation of peroxisome proliferator-activated receptors by e6-associated protein. PPAR Res. 2008; 2008:746935.
|
|
|
|
|
28.
|
He P, Borland MG, Zhu B, Sharma AK, Amin S, El-Bayoumy K, Gonzalez FJ, Peters JM. Effect of ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) in human lung cancer cell lines. Toxicology. 2008 Dec 5; 254(1-2):112-7.
|
|
|
|
|
29.
|
Bility MT, Devlin-Durante MK, Blazanin N, Glick AB, Ward JM, Kang BH, Kennett MJ, Gonzalez FJ, Peters JM. Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPAR beta/delta) inhibits chemically induced skin tumorigenesis. Carcinogenesis. 2008 Dec; 29(12):2406-14.
|
|
|
|
|
30.
|
Maher JM, Aleksunes LM, Dieter MZ, Tanaka Y, Peters JM, Manautou JE, Klaassen CD. Nrf2- and PPAR alpha-mediated regulation of hepatic Mrp transporters after exposure to perfluorooctanoic acid and perfluorodecanoic acid. Toxicol Sci. 2008 Dec; 106(2):319-28.
|
|
|
|
|
31.
|
Han JK, Lee HS, Yang HM, Hur J, Jun SI, Kim JY, Cho CH, Koh GY, Peters JM, Park KW, Cho HJ, Lee HY, Kang HJ, Oh BH, Park YB, Kim HS. Peroxisome proliferator-activated receptor-delta agonist enhances vasculogenesis by regulating endothelial progenitor cells through genomic and nongenomic activations of the phosphatidylinositol 3-kinase/Akt pathway. Circulation. 2008 Sep 2; 118(10):1021-33.
|
|
|
|
|
32.
|
Borland MG, Foreman JE, Girroir EE, Zolfaghari R, Sharma AK, Amin S, Gonzalez FJ, Ross AC, Peters JM. Ligand activation of peroxisome proliferator-activated receptor-beta/delta inhibits cell proliferation in human HaCaT keratinocytes. Mol Pharmacol. 2008 Nov; 74(5):1429-42.
|
|
|
|
|
33.
|
Peters JM, Hollingshead HE, Gonzalez FJ. Role of peroxisome-proliferator-activated receptor beta/delta (PPARbeta/delta) in gastrointestinal tract function and disease. Clin Sci (Lond). 2008 Aug; 115(4):107-27.
|
|
|
|
|
34.
|
Shan W, Palkar PS, Murray IA, McDevitt EI, Kennett MJ, Kang BH, Isom HC, Perdew GH, Gonzalez FJ, Peters JM. Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression. Toxicol Sci. 2008 Oct; 105(2):418-28.
|
|
|
|
|
35.
|
Girroir EE, Hollingshead HE, He P, Zhu B, Perdew GH, Peters JM. Quantitative expression patterns of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) protein in mice. Biochem Biophys Res Commun. 2008 Jul 4; 371(3):456-61.
|
|
|
|
|
36.
|
Müller R, Kömhoff M, Peters JM, Müller-Brüsselbach S. A Role for PPARbeta/delta in Tumor Stroma and Tumorigenesis. PPAR Res. 2008; 2008:534294.
|
|
|
|
|
37.
|
Shan W, Nicol CJ, Ito S, Bility MT, Kennett MJ, Ward JM, Gonzalez FJ, Peters JM. Peroxisome proliferator-activated receptor-beta/delta protects against chemically induced liver toxicity in mice. Hepatology. 2008 Jan; 47(1):225-35.
|
|
|
|
|
38.
|
Girroir EE, Hollingshead HE, Billin AN, Willson TM, Robertson GP, Sharma AK, Amin S, Gonzalez FJ, Peters JM. Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands inhibit growth of UACC903 and MCF7 human cancer cell lines. Toxicology. 2008 Jan 14; 243(1-2):236-43.
|
|
|
|
|
39.
|
Guo D, Sarkar J, Suino-Powell K, Xu Y, Matsumoto K, Jia Y, Yu S, Khare S, Haldar K, Rao MS, Foreman JE, Monga SP, Peters JM, Xu HE, Reddy JK. Induction of nuclear translocation of constitutive androstane receptor by peroxisome proliferator-activated receptor alpha synthetic ligands in mouse liver. J Biol Chem. 2007 Dec 14; 282(50):36766-76.
|
|
|
|
|
40.
|
Hollingshead HE, Borland MG, Billin AN, Willson TM, Gonzalez FJ, Peters JM. Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) and inhibition of cyclooxygenase 2 (COX2) attenuate colon carcinogenesis through independent signaling mechanisms. Carcinogenesis. 2008 Jan; 29(1):169-76.
|
|
|
|
|
41.
|
Müller-Brüsselbach S, Ebrahimsade S, Jäkel J, Eckhardt J, Rapp UR, Peters JM, Moll R, Müller R. Growth of transgenic RAF-induced lung adenomas is increased in mice with a disrupted PPARbeta/delta gene. Int J Oncol. 2007 Sep; 31(3):607-11.
|
|
|
|
|
42.
|
Hollingshead HE, Killins RL, Borland MG, Girroir EE, Billin AN, Willson TM, Sharma AK, Amin S, Gonzalez FJ, Peters JM. Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands do not potentiate growth of human cancer cell lines. Carcinogenesis. 2007 Dec; 28(12):2641-9.
|
|
|
|
|
43.
|
Abdollahi A, Schwager C, Kleeff J, Esposito I, Domhan S, Peschke P, Hauser K, Hahnfeldt P, Hlatky L, Debus J, Peters JM, Friess H, Folkman J, Huber PE. Transcriptional network governing the angiogenic switch in human pancreatic cancer. Proc Natl Acad Sci U S A. 2007 Jul 31; 104(31):12890-5.
|
|
|
|
|
44.
|
Müller-Brüsselbach S, Kömhoff M, Rieck M, Meissner W, Kaddatz K, Adamkiewicz J, Keil B, Klose KJ, Moll R, Burdick AD, Peters JM, Müller R. Deregulation of tumor angiogenesis and blockade of tumor growth in PPARbeta-deficient mice. EMBO J. 2007 Aug 8; 26(15):3686-98.
|
|
|
|
|
45.
|
Hollingshead HE, Morimura K, Adachi M, Kennett MJ, Billin AN, Willson TM, Gonzalez FJ, Peters JM. PPARbeta/delta protects against experimental colitis through a ligand-independent mechanism. Dig Dis Sci. 2007 Nov; 52(11):2912-9.
|
|
|
|
|
46.
|
Coleman JD, Prabhu KS, Thompson JT, Reddy PS, Peters JM, Peterson BR, Reddy CC, Vanden Heuvel JP. The oxidative stress mediator 4-hydroxynonenal is an intracellular agonist of the nuclear receptor peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta). Free Radic Biol Med. 2007 Apr 15; 42(8):1155-64.
|
|
|
|
|
47.
|
Burdick AD, Bility MT, Girroir EE, Billin AN, Willson TM, Gonzalez FJ, Peters JM. Ligand activation of peroxisome proliferator-activated receptor-beta/delta(PPARbeta/delta) inhibits cell growth of human N/TERT-1 keratinocytes. Cell Signal. 2007 Jun; 19(6):1163-71.
|
|
|
|
|
48.
|
Woods CG, Burns AM, Maki A, Bradford BU, Cunningham ML, Connor HD, Kadiiska MB, Mason RP, Peters JM, Rusyn I. Sustained formation of alpha-(4-pyridyl-1-oxide)-N-tert-butylnitrone radical adducts in mouse liver by peroxisome proliferators is dependent upon peroxisome proliferator-activated receptor-alpha, but not NADPH oxidase. Free Radic Biol Med. 2007 Feb 1; 42(3):335-42.
|
|
|
|
|
49.
|
Rusyn I, Peters JM, Cunningham ML. Modes of action and species-specific effects of di-(2-ethylhexyl)phthalate in the liver. Crit Rev Toxicol. 2006 May; 36(5):459-79.
|
|
|
|
|
50.
|
Marin HE, Peraza MA, Billin AN, Willson TM, Ward JM, Kennett MJ, Gonzalez FJ, Peters JM. Ligand activation of peroxisome proliferator-activated receptor beta inhibits colon carcinogenesis. Cancer Res. 2006 Apr 15; 66(8):4394-401.
|
|
|
|
|
51.
|
Lee CH, Olson P, Hevener A, Mehl I, Chong LW, Olefsky JM, Gonzalez FJ, Ham J, Kang H, Peters JM, Evans RM. PPARdelta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci U S A. 2006 Feb 28; 103(9):3444-9.
|
|
|
|
|
52.
|
Yang Q, Yamada A, Kimura S, Peters JM, Gonzalez FJ. Alterations in skin and stratified epithelia by constitutively activated PPARalpha. J Invest Dermatol. 2006 Feb; 126(2):374-85.
|
|
|
|
|
53.
|
Kim DJ, Prabhu KS, Gonzalez FJ, Peters JM. Inhibition of chemically induced skin carcinogenesis by sulindac is independent of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta). Carcinogenesis. 2006 May; 27(5):1105-12.
|
|
|
|
|
54.
|
Peraza MA, Burdick AD, Marin HE, Gonzalez FJ, Peters JM. The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR). Toxicol Sci. 2006 Apr; 90(2):269-95.
|
|
|
|
|
55.
|
Murray IA, Reen RK, Leathery N, Ramadoss P, Bonati L, Gonzalez FJ, Peters JM, Perdew GH. Evidence that ligand binding is a key determinant of Ah receptor-mediated transcriptional activity. Arch Biochem Biophys. 2005 Oct 1; 442(1):59-71.
|
|
|
|
|
56.
|
Patel RD, Kim DJ, Peters JM, Perdew GH. The aryl hydrocarbon receptor directly regulates expression of the potent mitogen epiregulin. Toxicol Sci. 2006 Jan; 89(1):75-82.
|
|
|
|
|
57.
|
Burdick AD, Kim DJ, Peraza MA, Gonzalez FJ, Peters JM. The role of peroxisome proliferator-activated receptor-beta/delta in epithelial cell growth and differentiation. Cell Signal. 2006 Jan; 18(1):9-20.
|
|
|
|
|
58.
|
Polak PE, Kalinin S, Dello Russo C, Gavrilyuk V, Sharp A, Peters JM, Richardson J, Willson TM, Weinberg G, Feinstein DL. Protective effects of a peroxisome proliferator-activated receptor-beta/delta agonist in experimental autoimmune encephalomyelitis. J Neuroimmunol. 2005 Nov; 168(1-2):65-75.
|
|
|
|
|
59.
|
Peters JM, Cheung C, Gonzalez FJ. Peroxisome proliferator-activated receptor-alpha and liver cancer: where do we stand? J Mol Med (Berl). 2005 Oct; 83(10):774-85.
|
|
|
|
|
60.
|
Clemencet MC, Muzio G, Trombetta A, Peters JM, Gonzalez FJ, Canuto RA, Latruffe N. Differences in cell proliferation in rodent and human hepatic derived cell lines exposed to ciprofibrate. Cancer Lett. 2005 May 26; 222(2):217-26.
|
|
|
|
|
61.
|
Kim DJ, Murray IA, Burns AM, Gonzalez FJ, Perdew GH, Peters JM. Peroxisome proliferator-activated receptor-beta/delta inhibits epidermal cell proliferation by down-regulation of kinase activity. J Biol Chem. 2005 Mar 11; 280(10):9519-27.
|
|
|
|
|
62.
|
Duez H, Lefebvre B, Poulain P, Torra IP, Percevault F, Luc G, Peters JM, Gonzalez FJ, Gineste R, Helleboid S, Dzavik V, Fruchart JC, Fiévet C, Lefebvre P, Staels B. Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation. Arterioscler Thromb Vasc Biol. 2005 Mar; 25(3):585-91.
|
|
|
|
|
63.
|
Reed KR, Sansom OJ, Hayes AJ, Gescher AJ, Winton DJ, Peters JM, Clarke AR. PPARdelta status and Apc-mediated tumourigenesis in the mouse intestine. Oncogene. 2004 Nov 25; 23(55):8992-6.
|
|
|
|
|
64.
|
Peters JM, Kato S, Gonzalez FJ. The United States-Japan workshop on: The role of nuclear receptors in carcinogenesis. Mol Carcinog. 2004 Oct; 41(2):77-84.
|
|
|
|
|
65.
|
Nakajima T, Kamijo Y, Tanaka N, Sugiyama E, Tanaka E, Kiyosawa K, Fukushima Y, Peters JM, Gonzalez FJ, Aoyama T. Peroxisome proliferator-activated receptor alpha protects against alcohol-induced liver damage. Hepatology. 2004 Oct; 40(4):972-80.
|
|
|
|
|
66.
|
Hays T, Rusyn I, Burns AM, Kennett MJ, Ward JM, Gonzalez FJ, Peters JM. Role of peroxisome proliferator-activated receptor-alpha (PPARalpha) in bezafibrate-induced hepatocarcinogenesis and cholestasis. Carcinogenesis. 2005 Jan; 26(1):219-27.
|
|
|
|
|
67.
|
Bility MT, Thompson JT, McKee RH, David RM, Butala JH, Vanden Heuvel JP, Peters JM. Activation of mouse and human peroxisome proliferator-activated receptors (PPARs) by phthalate monoesters. Toxicol Sci. 2004 Nov; 82(1):170-82.
|
|
|
|
|
68.
|
Matsusue K, Peters JM, Gonzalez FJ. PPARbeta/delta potentiates PPARgamma-stimulated adipocyte differentiation. FASEB J. 2004 Sep; 18(12):1477-9.
|
|
|
|
|
69.
|
Miyazaki M, Dobrzyn A, Sampath H, Lee SH, Man WC, Chu K, Peters JM, Gonzalez FJ, Ntambi JM. Reduced adiposity and liver steatosis by stearoyl-CoA desaturase deficiency are independent of peroxisome proliferator-activated receptor-alpha. J Biol Chem. 2004 Aug 13; 279(33):35017-24.
|
|
|
|
|
70.
|
Nicol CJ, Yoon M, Ward JM, Yamashita M, Fukamachi K, Peters JM, Gonzalez FJ. PPARgamma influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis. Carcinogenesis. 2004 Sep; 25(9):1747-55.
|
|
|
|
|
71.
|
Harman FS, Nicol CJ, Marin HE, Ward JM, Gonzalez FJ, Peters JM. Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis. Nat Med. 2004 May; 10(5):481-3.
|
|
|
|
|
72.
|
Kim DJ, Akiyama TE, Harman FS, Burns AM, Shan W, Ward JM, Kennett MJ, Gonzalez FJ, Peters JM. Peroxisome proliferator-activated receptor beta (delta)-dependent regulation of ubiquitin C expression contributes to attenuation of skin carcinogenesis. J Biol Chem. 2004 May 28; 279(22):23719-27.
|
|
|
|
|
73.
|
Akiyama TE, Lambert G, Nicol CJ, Matsusue K, Peters JM, Brewer HB, Gonzalez FJ. Peroxisome proliferator-activated receptor beta/delta regulates very low density lipoprotein production and catabolism in mice on a Western diet. J Biol Chem. 2004 May 14; 279(20):20874-81.
|
|
|
|
|
74.
|
Rusyn I, Asakura S, Pachkowski B, Bradford BU, Denissenko MF, Peters JM, Holland SM, Reddy JK, Cunningham ML, Swenberg JA. Expression of base excision DNA repair genes is a sensitive biomarker for in vivo detection of chemical-induced chronic oxidative stress: identification of the molecular source of radicals responsible for DNA damage by peroxisome proliferators. Cancer Res. 2004 Feb 1; 64(3):1050-7.
|
|
|
|
|
75.
|
Tien ES, Gray JP, Peters JM, Vanden Heuvel JP. Comprehensive gene expression analysis of peroxisome proliferator-treated immortalized hepatocytes: identification of peroxisome proliferator-activated receptor alpha-dependent growth regulatory genes. Cancer Res. 2003 Sep 15; 63(18):5767-80.
|
|
|
|
|
76.
|
Peters JM, Aoyama T, Burns AM, Gonzalez FJ. Bezafibrate is a dual ligand for PPARalpha and PPARbeta: studies using null mice. Biochim Biophys Acta. 2003 Jun 10; 1632(1-3):80-9.
|
|
|
|
|
77.
|
Klaunig JE, Babich MA, Baetcke KP, Cook JC, Corton JC, David RM, DeLuca JG, Lai DY, McKee RH, Peters JM, Roberts RA, Fenner-Crisp PA. PPARalpha agonist-induced rodent tumors: modes of action and human relevance. Crit Rev Toxicol. 2003; 33(6):655-780.
|
|
|
|
|
78.
|
Ntambi JM, Choi Y, Park Y, Peters JM, Pariza MW. Effects of conjugated linoleic acid (CLA) on immune responses, body composition and stearoyl-CoA desaturase. Can J Appl Physiol. 2002 Dec; 27(6):617-28.
|
|
|
|
|
79.
|
Ripp SL, Fitzpatrick JL, Peters JM, Prough RA. Induction of CYP3A expression by dehydroepiandrosterone: involvement of the pregnane X receptor. Drug Metab Dispos. 2002 May; 30(5):570-5.
|
|
|
|
|
80.
|
Rosenberger TA, Hovda JT, Peters JM. Targeted disruption of peroxisomal proliferator-activated receptor beta (delta) results in distinct gender differences in mouse brain phospholipid and esterified FA levels. Lipids. 2002 May; 37(5):495-500.
|
|
|
|
|
81.
|
Peters JM, Park Y, Gonzalez FJ, Pariza MW. Influence of conjugated linoleic acid on body composition and target gene expression in peroxisome proliferator-activated receptor alpha-null mice. Biochim Biophys Acta. 2001 Oct 31; 1533(3):233-42.
|
|
|
|
|
82.
|
Peters JM, Lee SS, Li W, Ward JM, Gavrilova O, Everett C, Reitman ML, Hudson LD, Gonzalez FJ. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). Mol Cell Biol. 2000 Jul; 20(14):5119-28.
|
|
|
|
|
83.
|
Peters JM, Rusyn I, Rose ML, Gonzalez FJ, Thurman RG. Peroxisome proliferator-activated receptor alpha is restricted to hepatic parenchymal cells, not Kupffer cells: implications for the mechanism of action of peroxisome proliferators in hepatocarcinogenesis. Carcinogenesis. 2000 Apr; 21(4):823-6.
|
|
|
|